PITTSBURGH--(BUSINESS WIRE)--Helomics Corporation, a privately held comprehensive personalized healthcare company that develops innovative next generation diagnostics for the oncology field, announced today that it will present at the Canaccord Genuity Medical Technology & Diagnostics Forum to be held November 19, 2015, at The Westin New York Grand Central in New York.
Dane Saglio, Vice President and Chief Financial Officer of Helomics, will provide an overview of the Company’s business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
|
Event: |
Canaccord Genuity Medical Technology and Diagnostics Forum |
||||||
|
Date: |
Thursday, November 19, 2015 | ||||||
|
Time: |
9:00AM | ||||||
|
Location: |
The Westin New York Grand Central | ||||||
About Helomics® Corporation
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.